Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination
Teresa Po‐Yu Chiang(Johns Hopkins University), William A. Werbel(Johns Hopkins University), Robin K. Avery(Johns Hopkins University), Jake D. Kim(Johns Hopkins University), Aura T. Abedon(Johns Hopkins University), Allan B. Massie(Johns Hopkins University), Dorry L. Segev(New York University), Jonathan Mitchell(Johns Hopkins University), Daniel Warren(Johns Hopkins University), Jacqueline Garonzik‐Wang(University of Wisconsin–Madison), Andrew Pekosz(Johns Hopkins University), Aaron A.R. Tobian(Johns Hopkins University), Andrew H. Karaba(Johns Hopkins University), Macey L. Levan(New York University), Letitia Thomas(Johns Hopkins University), Jennifer L. Alejo(Johns Hopkins University), William Clarke(Johns Hopkins University)
Cited by 19
Related Papers
Foot strike patterns and collision forces in habitually barefoot versus shod runners
|Nature|2010|1.4k
Clinical Practice Guidelines From the AABB
|JAMA|2016|1.1k
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
|American Journal of Transplantation|2017|1k
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
|JAMA|2021|1k
Deployment of convalescent plasma for the prevention and treatment of COVID-19
|Journal of Clinical Investigation|2020|863